tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2021-99-7-55-62tiblj-1556Research ArticleОБЗОРREVIEWЛекарственно-индуцированные поражения легких противоопухолевыми препаратами: диагностика, особенности клинического течения, факторы риска, дифференциальный диагноз, лечение, профилактика. Часть 1Lung Injury Induced by Antitumor Drugs: Diagnosis, Features of the Clinical Course, Risk Factors, Differential Diagnosis, Treatment, and Prevention. Part 1ОрловаН. В.OrlovаN. V.

Орлова Наталья Васильевна – доктор медицинских наук, профессор.

117997, Москва, ул. Островитянова, д. 1.

Тел.: +7 (495) 674-48-68.

Natalia V. Orlova – Doctor of Medical Sciences, Professor.

1, Ostrovityanova St., Moscow, 117997

Phone: +7 (495) 674-48-68.

vrach315@yandex.ruОстроумоваО. Д.OstroumovаO. D.

Остроумова Ольга Дмитриевна – доктор медицинских наук, профессор, заведующая кафедрой терапии и полиморбидной патологии.

125993, Москва, ул. Баррикадная, д. 2/1, стр. 1.

Тел.: +7 (495) 945-11-28.

Olga D. Ostoumova – Doctor of Medical Sciences, Professor, Head of Department of Therapy and Polymorbid Pathology.

2/1, Build. 1. Barrikadnaya St., Moscow, 125993

Phone: +7 (495) 945-11-28.

ostroumova.olga@mail.ruШихЕ. В.ShikhE. V.

Ших Евгения Валерьевна – доктор медицинских наук, профессор, заведующая кафедрой клинической фармакологии и пропедевтики внутренних болезней, директор Института профессионального образования.

119991, Москва, ул. Трубецкая, д. 8 стр. 2.

Тел.: +7 (495) 609-19-91.

Evgeniya V. Shikh – Doctor of Medical Sciences, Professor, Head of Department of Clinical Pharmacology and Propedeutics of Internal Diseases, Director of Professional Education Institute.

8, Bd. 2, Trubetskaya St., Moscow, 119991

Phone: +7 (495) 609-19-91.

chih@mail.ruСмердинС. В.SmerdinS. V.

Смердин Сергей Викторович – доктор медицинских наук, профессор, главный врач.

141132, Московская область, Щелковский район, д. Сукманиха, влад. 1Б.

Тел.: +7 (499) 978-02-43.

Sergey V. Smerdin – Doctor of Medical Sciences, Professor, Chief Physician.

1b, Village of Sukmanikha, Schelkovsky Raion, Moscow Region, 141132

Phone: +7 (499) 978-02-43.

smerdin_030@mail.ruРеброваЕ. В.RebrovаE. V.

Реброва Екатерина Владиславовна – кандидат медицинских наук, доцент кафедры клинической фармакологии и пропедевтики внутренних болезней.

119991, Москва, ул. Трубецкая, д. 8 стр. 2.

Тел.: +7 (495) 609-14-00.

Ekaterina V. Rebrova – Candidate of Medical Sciences, Associate Professor of Department of Clinical Pharmacology and Propedeutics of Internal Diseases.

8, Bd. 2, Trubetskaya St., Moscow, 119991

Phone: +7 (495) 609-14-00.

katrina1987@rambler.ruДёВ. А.DyoV. А.

Дё Валерия Анатольевна – ординатор кафедры терапии и полиморбидной патологии.

Тел.: +7 (495) 945-11-28.

125993, Москва, ул. Баррикадная, д. 2/1, стр. 1.

Valeria A. Dyo – Resident of Department of Therapy and Polymorbid Pathology.

2/1, Build. 1. Barrikadnaya St., Moscow, 125993

Phone: +7 (495) 945-11-28.

devaleria97@mail.ruФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» МЗ РФРоссияPirogov Russian National Research Medical UniversityRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФРоссияRussian Medical Academy of On-going Professional EducationRussian FederationФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. СеченоваРоссияI. M. Sechenov First Moscow State Medical UniversityRussian FederationГБУЗ МО «Московский областной клинический противотуберкулезный диспансер»РоссияMoscow Regional Clinical TB DispensaryRussian Federation2021180820219975562Copyright © Орлова Н.В., Остроумова О.Д., Ших Е.В., Смердин С.В., Реброва Е.В., Дё В.А., 20212021Орлова Н.В., Остроумова О.Д., Ших Е.В., Смердин С.В., Реброва Е.В., Дё В.А.Orlovа N.V., Ostroumovа O.D., Shikh E.V., Smerdin S.V., Rebrovа E.V., Dyo V.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1556

Проанализировано 57 источников литературы о пневмотоксичности противоопухолевых препаратов. Установлено, что на развитие пневмотоксических эффектов могут оказывать влияние такие факторы риска, как пол, возраст, курение, сопутствующие заболевания, продолжительность терапии. Симптомы лекарственного поражения легких противоопухолевыми препаратами неспецифичны, что затрудняет их своевременную диагностику. Для профилактики, ранней диагностики и своевременной коррекции лекарственно-индуцированного поражения легких на фоне противоопухолевой терапии необходима информированность практикующих врачей разных специальностей, прежде всего терапевтов, пульмонологов, фтизиатров, онкологов.

57 publications on pneumotoxicity of antitumor drugs were analyzed. It was found that the development of pneumotoxic effects could be influenced by risk factors such as gender, age, tobacco smoking, comorbidities, and duration of therapy. Symptoms of lung injury induced by antitumor drugs are nonspecific thus it is difficult to diagnose them promptly. For prevention, early diagnosis and timely management of drug-induced lung injury during antineoplastic therapy, it is necessary to raise awareness of such a condition in practitioners of different specialties, primarily general practitioners, pulmonologists, phthisiologists, and oncologists.

лекарственно-индуцированные поражения легкихпротивоопухолевая терапияпневмотоксичностьнежелательные лекарственные реакцииdrug-induced lung injuryantineoplastic therapypneumotoxicityadverse drug reactionsReferencesАнаев Э. Х. Лекарственно-индуцированное интерстициальное заболевание легких: подходы к диагностике и лечению // Терапевтический архив. – 2020. – Т. 92, № 3. – С. 84-91.Аnaev E.Kh. Drug-induced interstitial lung disease: approaches to diagnostics and treatment, Terapevticheskiy Arkhiv, 2020, vol. 92, no. 3, pp. 84-91. (In Russ.).Майорова О. А. Фармакогенетика: индивидуальные особенности метаболизма // Качественная клиническая практика. ‒ 2002. ‒ № 4. – С. 2-10.Mayorova O.I. Pharmacogenetics: individual characteristics of metabolism. Kachestvennaya Klinicheskaya Praktika, 2002, no. 4, pp. 2-10. (In Russ.).Постников С. С., Грацианская А. Н., Костылева М. Н. Лекарственная патология легких // Педиатрия. Журнал им. Г. Н. Сперанского. ‒ 2013. ‒ № 92 (3). ‒ С. 130-135.Postnikov S.S., Gratsianskaya А.N., Kostyleva M.N. Drug-induced lung disorders. Pediatriya. Journal im. G.N. Speranskogo, 2013, no. 92 (3), pp. 130-135. (In Russ.).Сычев Д. А., Остроумова О. Д., Переверзев А. П., Кочетков А. И., Остроумова Т. М., Клепикова М. В., Аляутдинова И. А., Голобородова И. В. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике // Фармаконадзор. Фарматека. ‒ 2020. ‒ № 27 (6). ‒ С. 113-126.Sychev D.А., Ostroumova O.D., Pereverzev А.P., Kochetkov А.I., Ostroumova T.M., Klepikova M.V., Аlyautdinova I.А., Goloborodova I.V. Drug-induced diseases: approaches to diagnosis, management and prevention. Pharmakonadzor. Pharmateka, 2020, no. 27 (6), pp. 113-126. (In Russ.).Abdel-Rahman O., Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis // Ther. Adv. Respir. Dis. ‒ 2016. ‒ № 10. – Р. 183-193.Abdel-Rahman O., Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther. Adv. Respir. Dis., 2016, no. 10, pp. 183-193.Albrecht E., Bayon V., Hirotsu C., Al Ja'bari A., Heinzer R. Intrathecal morphine and sleep apnoea severity in patients undergoing hip arthroplasty: a randomised, controlled, triple-blinded trial // Br. J. Anaesth. ‒ 2020. ‒ № 125 (5). – Р. 811-817.Albrecht E., Bayon V., Hirotsu C., Al Ja'bari A., Heinzer R. Intrathecal morphine and sleep apnoea severity in patients undergoing hip arthroplasty: a randomised, controlled, triple-blinded trial. Br. J. Anaesth., 2020, no. 125 (5), pp. 811-817.Anan K., Ichikado K., Kawamura K. Clinical characteristics and prognosis of drug-associated acute respiratory distress syndrome compared with non-drug-associated acute respiratory distress syndrome: a single-centre retrospective study in Japan // BMJ Open. – 2017. ‒ № 7. ‒ Р. e015330.Anan K., Ichikado K., Kawamura K. Clinical characteristics and prognosis of drug-associated acute respiratory distress syndrome compared with non-drug-associated acute respiratory distress syndrome: a single-centre retrospective study in Japan. BMJ Open, 2017, no. 7, pp. e015330.Ananthakrishnan A. N., Attila T., Otterson M. F., Lipchik R. J., Massey B. T., Komorowski R. A., Binion D. G. Severe pulmonary toxicity after azathioprine/6- mercaptopurine initiation for the treatment of inflammatory bowel disease // J. Clin. Gastroenterol. ‒ 2007. ‒ № 41. – Р. 682-688.Ananthakrishnan A.N., Attila T., Otterson M.F., Lipchik R.J., Massey B.T., Komorowski R.A., Binion D.G. Severe pulmonary toxicity after azathioprine/6- mercaptopurine initiation for the treatment of inflammatory bowel disease. J. Clin. Gastroenterol., 2007, no. 41, pp. 682-688.Ando S. S., Kawai K. K., Kuriyagawa K. K., Sekido N., Miyanaga N., Shimazui T., Akaza H. Extremely acute exacerbation of interstitial pneumonia after interferonalpha treatment for metastatic renal cell carcinoma // Int. J. Clin. Oncol. ‒ 2009. ‒ Vol. 14, № 2. – Р. 171-173.Ando S.S., Kawai K.K., Kuriyagawa K.K., Sekido N., Miyanaga N., Shimazui T., Akaza H. Extremely acute exacerbation of interstitial pneumonia after interferonalpha treatment for metastatic renal cell carcinoma. Int. J. Clin. Oncol., 2009, vol. 14, no. 2, pp. 171-173.Ando M., Okamoto I., Yamamoto N., Takeda K., Tamura K., Seto T., Ariyoshi Y., Fukuoka M. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib // Clin. Oncol. – 2006. – № 24 (16). – P. 2549-2556.Ando M., Okamoto I., Yamamoto N., Takeda K., Tamura K., Seto T., Ariyoshi Y., Fukuoka M. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. Clin. Oncol., 2006, no. 24 (16), pp. 2549-2556.Balk R. A. Methotrexate-induced lung injury // Wolters Kluwer. – 2020 Nov. Available from: https://www.uptodate.com/contents/methotrexate-inducedlung-injury.Balk R.A. Methotrexate-induced lung injury. Wolters Kluwer, 2020 Nov. Available from: https://www.uptodate.com/contents/methotrexate-inducedlung-injury.Bonniaud P., Georges M., Favrolt N., Camus P. [Drug-induced interstitial lung diseases] // Rev Prat. ‒ 2014. ‒ № 64. ‒ Р. 951.Bonnard P., Georges M., Favrolt N., Camus P. Drug-induced interstitial lung diseases. Rev Prat., 2014, no. 64, pp. 951.Camus P., von der Thüsen J., Hansell D. M., Colby T. V. Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs? // Eur. Respir. J. ‒ 2014. ‒ № 44. ‒ Р. 289.Camus P., von der Thüsen J., Hansell D.M., Colby T.V. Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs? Eur. Respir. J., 2014, no. 44, pp. 289.Cao T. M., Negrin R. S., Stockerl-Goldstein K. E., Johnston L. J., Shizuru J. A., Taylor T. L., Rizk N. W., Wong R. M., Blume K. G., Hu W. W. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation // Biol. Blood Marrow Transplant. ‒ 2000. ‒ № 6 (4). – Р. 387-394.Cao T.M., Negrin R.S., Stockerl-Goldstein K.E., Johnston L.J., Shizuru J.A., Taylor T.L., Rizk N.W., Wong R.M., Blume K.G., Hu W.W. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol. Blood Marrow Transplant., 2000, no. 6 (4), pp. 387-394.Charpidou A. G., Gkiozos I., Tsimpoukis S., Apostolaki D., Dilana K. D., Karapanagiotou E. M., Syrigos K. N. Therapy-induced Toxicity of the Lungs: An Overview // Anticancer Research. – 2009. – № 29. – P. 631-640.Charpidou A.G., Gkiozos I., Tsimpoukis S., Apostolaki D., Dilana K.D., Karapanagiotou E.M., Syrigos K.N. Therapy-induced Toxicity of the Lungs: An Overview. Anticancer Research, 2009, no. 29, pp. 631-640.Das B., Shoemaker L., Subramanian S., Johnsrude C., Recto M., Austin E. Acute sirolimus pulmonary toxicity in an infant heart transplant recipient: case report and literature review // J. Heart Lung Transplant. ‒ 2007. ‒ № 26. – Р. 296-298.Das B., Shoemaker L., Subramanian S., Johnsrude C., Recto M., Austin E. Acute sirolimus pulmonary toxicity in an infant heart transplant recipient: case report and literature review. J. Heart Lung Transplant., 2007, no. 26, pp. 296-298.Dhokarh R., Li G., Schmickl C. N. et al. Drug-associated acute lung injury: a population-based cohort study // Chest. ‒ 2012. ‒ № 142. ‒ Р. 845.Dhokarh R., Li G., Schmickl C.N. et al. Drug-associated acute lung injury: a population-based cohort study. Chest, 2012, no. 142, pp. 845.Dimopoulou I., Bamias A., Lyberopoulos P., Dimopoulos M. A. Pulmonary toxicity from novel antineoplastic agents // Ann. Oncol. ‒ 2006. ‒ № 17 (3). – Р. 372-379.Dimopoulou I., Bamias A., Lyberopoulos P., Dimopoulos M.A. Pulmonary toxicity from novel antineoplastic agents. Ann. Oncol., 2006, no. 17 (3), pp. 372-379.Duley J. A., Marinaki A. M., Arenas M., Florin T. H. J. Do ITPA and TPMT genotypes predict the development of side effects to AZA? // Gut. ‒ 2006. ‒ Vol. 55, № 7. – Р. 1048.Duley J.A., Marinaki A.M., Arenas M., Florin T. H.J. Do ITPA and TPMT genotypes predict the development of side effects to AZA? Gut., 2006, vol. 55, no. 7, pp. 1048.El-Melouk W., Jazieh A. R. Novel drug-induced pulmonary complications in cancer patients you can save life! // Current Respiratory Medicine Reviews. – 2016. ‒ № 12 (2).El-Melouk W., Jazieh A.R. Novel drug-induced pulmonary complications in cancer patients you can save life! Current Respiratory Medicine Reviews, 2016, no. 12 (2).Fabien Maldonado F., Limper A. H., Cass A. S. Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment // https://www.uptodate.com/contents/pulmonary-toxicity-associated-with-systemic-antineoplastic-therapy-clinical-presentation-diagnosis-and-treatment.Fabien Maldonado F., Limper A. H., Cass A. S. Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment.https://www.uptodate.com/contents/pulmonary-toxicity-associated-with-systemic-antineoplastic-therapy-clinical-presentation-diagnosis-and-treatment.Froudarakis M., Hatzimichael E., Kyriazopoulou L., Lagos K., Pappas P., Tzakos A. G., Karavasilis V., Daliani D., Papandreou Ch., Briasoulis E. Revisiting bleomycin from pathophysiology to safe clinical use // Crit. Rev. Oncol. Hematol. ‒ 2013. ‒ № 87 (1). – Р. 90-100.Froudarakis M., Hatzimichael E., Kyriazopoulou L., Lagos K., Pappas P., Tzakos A. G., Karavasilis V., Daliani D., Papandreou Ch., Briasoulis E. Revisiting bleomycin from pathophysiology to safe clinical use. Crit. Rev. Oncol. Hematol., 2013, no. 87 (1), pp. 90-100.Fujimoto D., Kato R., Morimoto T. et al. Characteristics and prognostic impact of pneumonitis during systemic anti-cancer therapy in patients with advanced non-small-cell lung cancer // PLoS One. ‒ 2016. ‒ № 11. ‒ Р. e0168465.Fujimoto D., Kato R., Morimoto T. et al. Characteristics and prognostic impact of pneumonitis during systemic anti-cancer therapy in patients with advanced non-small-cell lung cancer. PLoS One, 2016, no. 11, pp. e0168465.Haston C., Wang M. Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice // Human Molecular Genetics. ‒ 2002. ‒ № 11 (16). – Р. 1855-1863.Haston C., Wang M. Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. Human Molecular Genetics, 2002, no. 11 (16), pp. 1855-1863.Hayslip J., Fenning R. Safe administration of iodine-131 tositumo-mab after repeated infusion-related reactions to rituximab // Oncologist. ‒ 2007. ‒ № 12. – Р. 338-340.Hayslip J., Fenning R. Safe administration of iodine-131 tositumo-mab after repeated infusion-related reactions to rituximab. Oncologist, 2007, no. 12, pp. 338-340.Hecht J. R., Mitchell E., Chidiac T., Scroggin C., Hagenstad C., Spigel D., Marshall J., Cohn A., McCollum D., Stella P., Deeter R., Shahin S., Amado R. G. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer // J. Clin. Oncol. ‒ 2009. ‒ № 27. – Р. 672-680.Hecht J.R., Mitchell E., Chidiac T., Scroggin C., Hagenstad C., Spigel D., Marshall J., Cohn A., McCollum D., Stella P., Deeter R., Shahin S., Amado R.G. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol., 2009, no. 27, pp. 672-680.Heit J. A., Silverstein M. D., Mohr D. N., Petterson T. M., O'Fallon W. M., Melton 3rd. L. J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study // Arch. Intern. Med. ‒ 2000. – № 160. – Р. 809-815.Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton 3rd. L.J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch. Intern. Med., 2000, no. 160, pp. 809-815.Howell A., Pippen J., Elledge R. M., Mauriac L., Vergote I., Jones S. E., Come S. E., Osborne C. K., Robertson J. F. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials // Cancer. ‒ 2005. ‒ № 104. – Р. 236-239.Howell A., Pippen J., Elledge R.M., Mauriac L., Vergote I., Jones S.E., Come S.E., Osborne C.K., Robertson J.F. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer, 2005, no. 104, pp. 236-239.Imokawa S., Colby T. V., Leslie K. O., Helmers R. A. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients // Eur. Respir. J. ‒ 2000. ‒ № 15. – Р. 373-381.Imokawa S., Colby T.V., Leslie K.O., Helmers R.A. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur. Respir. J., 2000, no. 15, pp. 373-381.Inomata S., Takahashi H., Nagata M., Yamada G., Shiratori M., Tanaka H., Satoh M., Saitoh T., Sato T., Abe S. Acute lung injury as an adverse event of gefitinib // Anticancer Drugs. ‒ 2004. ‒ № 15. – Р. 461-467.Inomata S., Takahashi H., Nagata M., Yamada G., Shiratori M., Tanaka H., Satoh M., Saitoh T., Sato T., Abe S. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs, 2004, no. 15, pp. 461-467.Inoue A., Sugawara S., Yamazaki K., Maemondo M., Suzuki T., Gomi K., Takanashi Sh., Inoue Ch., Inage M., Yokouchi H., Watanabe H., Tsukamoto T., Saijo Ya., Ishimoto O., Hommura F., Nukiwa T. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402 // J. Clin. Oncol. ‒ 2008. ‒ № 26. – Р. 5401.Inoue A., Sugawara S., Yamazaki K., Maemondo M., Suzuki T., Gomi K., Takanashi Sh., Inoue Ch., Inage M., Yokouchi H., Watanabe H., Tsukamoto T., Saijo Ya., Ishimoto O., Hommura F., Nukiwa T. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J. Clin. Oncol., 2008, no. 26, pp. 5401.Jóna Á., Miltényi Z., Póliska S., Bálint B. L., Illés Á. Effect of Bleomycin Hydrolase Gene Polymorphism on Late Pulmonary Complications of Treatment for Hodgkin Lymphoma // PLOS One. ‒ 2016. ‒ № 11 (6). ‒ Р. е0157651.Jóna Á., Miltényi Z., Póliska S., Bálint B.L., Illés Á. Effect of bleomycin hydrolase gene polymorphism on late pulmonary complications of treatment for hodgkin lymphoma. PLOS One, 2016, no. 11 (6), pp. е0157651.Kinder A. J., Hassell A. B., Brand J., Brownfield A., Grove M., Shadforth M. F. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions // Rheumatology. ‒ 2005. ‒ № 44. – Р. 61-66.Kinder A.J., Hassell A.B., Brand J., Brownfield A., Grove M., Shadforth M.F. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology, 2005, no. 44, pp. 61-66.Konstantinides S., Meyer G., Becattini C., Bueno H., Geersing G-J., Harjola V. P., Huisman Menno V, Humbert M., Jennings C.S., Jiménez D., Kucher N., Lang I. M., Lankeit M., Lorusso R., Mazzolai L., Meneveau N., Áinle F. N., Prandoni P., Pruszczyk P., Righini M., Torbicki A., Belle E. V., Zamorano J. L. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) // Eur. Heart J. ‒ 2020. ‒ № 41. – Р. 543-603.Konstantinides S., Meyer G., Becattini C., Bueno H., Geersing G.J., Harjola V.P., Huisman Menno V, Humbert M., Jennings C.S., Jiménez D., Kucher N., Lang I.M., Lankeit M., Lorusso R., Mazzolai L., Meneveau N., Áinle F.N., Prandoni P., Pruszczyk P., Righini M., Torbicki A., Belle E.V., Zamorano J.L. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur. Heart J., 2020, no. 41, pp. 543-603.Kumar S., Mehra S. How drugs affect the lungs // Internet J. Pulm. Med. ‒ 2008. ‒ Vol. 9, № 2. – Р. 1-5.Kumar S., Mehra S. How drugs affect the lungs. Internet J. Pulm. Med., 2008, vol. 9, no. 2, pp. 1-5.Leader W. G., Mohundro B. L. Asthma and bronchospasm. drug induced diseases: prevention, detection, and management. 2nd ed. // Am. Soc. Health-System Pharmac. ‒ 2010. ‒ Chap. 22. – Р. 378-397.Leader W.G., Mohundro B.L. Asthma and bronchospasm. drug induced diseases: prevention, detection, and management. 2nd ed. Am. Soc. Health-System Pharmac, 2010, chap. 22, pp. 378-397.Lee M.-Y., Yoon S. Y., Kim K. H., Lee N., Kim H. Y., Hwang J. H., Jong-Ho Won J.-H. Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience // Korean J. Intern. Med. – 2021. – P. 1-10.Lee M.Y., Yoon S.Y., Kim K.H., Lee N., Kim H.Y., Hwang J.H., Jong-Ho Won J.H. Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience. Korean J. Intern. Med., 2021, pp. 1-10.Leger P., Limper A. H., Maldonado F. Pulmonary toxicities from conventional chemotherapy // Clin. Chest Med. ‒ 2017. ‒ № 38. ‒ Р. 209.Leger P., Limper A.H., Maldonado F. Pulmonary toxicities from conventional chemotherapy. Clin. Chest Med., 2017, no. 38, pp. 209.Li X., Shan B-E., Wang J., Xing L-P., Guo X-J., Zhang Y-H., Shi P-H., Wang Z-Y. Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials // PLoS One. ‒ 2013. ‒ № 8 (11). ‒ Р. e81897.Li X., Shan B.E., Wang J., Xing L.P., Guo X.J., Zhang Y.H., Shi P.H., Wang Z.Y. Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials. PLoS One, 2013, no. 8 (11), pp. e81897.Limper A.H. Chemotherapy-induced lung disease // Clin. Chest Med. ‒ 2004. ‒ № 25. – Р. 53.Limper A.H. Chemotherapy-induced lung disease. Clin. Chest Med., 2004, no. 25, pp. 53.Liote H., Liote F., Seroussi B., Mayaud C., Cadranel J. Rituximab-induced lung disease: A systematic literature review // Eur. Respir. J. ‒ 2010. ‒ № 35. – Р. 681-687.Liote H., Liote F., Seroussi B., Mayaud C., Cadranel J. Rituximab-induced lung disease: A systematic literature review. Eur. Respir. J., 2010, no. 35, pp. 681-687.Martin W. G., Ristow K. M., Habermann T. M., Colgan J. P., Witzig Th. E., Ansell S. E. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma // J. Clin. Oncol. ‒ 2005. ‒ № 23 (30). – Р. 7614-7620.Martin W.G., Ristow K.M., Habermann T.M., Colgan J.P., Witzig Th.E., Ansell S.E. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J. Clin. Oncol., 2005, no. 23 (30), pp. 7614-7620.Matsumoto K., Nakao S., Hasegawa S., Matsui T., Shimada K., Mukai R., Tanaka M., Uranishi H., Nakamura M. Analysis of drug-induced interstitial lung disease using the Japanese Adverse Drug Event Report database // SAGE. ‒ 2020. ‒ № 8. ‒ 2050312120918264.Matsumoto K., Nakao S., Hasegawa S., Matsui T., Shimada K., Mukai R., Tanaka M., Uranishi H., Nakamura M. Analysis of drug-induced interstitial lung disease using the Japanese Adverse Drug Event Report database. SAGE, 2020, no. 8, 2050312120918264.Nebeker J. R., Barach P., Samore M. H. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting // Ann. Intern. Med. ‒ 2004. ‒ № 140. ‒ Р. 795.Nebeker J.R., Barach P., Samore M.H. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann. Intern. Med., 2004, no. 140, pp. 795.Nivetha R., Arul B., Kothai R. Drug Induced Pulmonary Disease-A Mini Review // Research J. Pharm. and Tech. – 2019. – № 12 (9). – P. 4583-4588.Nivetha R., Arul B., Kothai R. Drug induced pulmonary disease-a mini review. Research J. Pharm. and Tech., 2019, no. 12 (9), pp. 4583-4588.O'Sullivan J. M., Huddart R. A., Norman A. R., Nicholls J., Dearnaley D. P., Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours // Ann. Oncology. ‒ 2003. ‒ Vol. 14, № 1. ‒ Р. 91-96.O'Sullivan J.M., Huddart R.A., Norman A.R., Nicholls J., Dearnaley D.P., Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann. Oncology, 2003, vol. 14, no. 1, pp. 91-96.Ozkan М., Dweik R. A. Drug-induced lung disease // Clevel. Clin. J. Med. ‒ 2001. ‒ № 68 (9). – Р. 782-795.Ozkan М., Dweik R.A. Drug-induced lung disease. Clevel. Clin. J. Med., 2001, no. 68 (9), pp. 782-795.Possick J. D. Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy // Clin. Chest Med. ‒ 2017. ‒ № 38. ‒ Р. 223.Possick J.D. Pulmonary toxicities from checkpoint immunotherapy for malignancy. Clin. Chest Med., 2017, no. 38, pp. 223.Rosenow 3rd E. C. Drug-induced pulmonary disease // Dis. Mon. ‒ 1994. ‒ № 40. – Р. 253-310.Rosenow 3rd E.C. Drug-induced pulmonary disease. Dis. Mon., 1994, no. 40, pp. 253-310.Ryu J. H. Chemotherapy-induced pulmonary toxicity in lung cancer patients // J. Thorac. Oncol. ‒ 2010. ‒ № 5. – Р. 1313.Ryu J.H. Chemotherapy-induced pulmonary toxicity in lung cancer patients. J. Thorac. Oncol., 2010, no. 5, pp. 1313.Starling N., Rao S., Cunningham D., Iveson T., Nicolson M., Coxon F., Middleton G., Daniel F., Oates J., Norman A.R. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group // J. Clin. Oncol. ‒ 2009. ‒ № 27. – Р. 3786-3793.Starling N., Rao S., Cunningham D., Iveson T., Nicolson M., Coxon F., Middleton G., Daniel F., Oates J., Norman A.R. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J. Clin. Oncol., 2009, no. 27, pp. 3786-3793.Takahashi H., Fujishima T., Koba H., Murakami S., Kurokawa K., Shibuya Y., Shiratori M, Kuroki Y., Abe S. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent // Am. J. Respir. Crit. Care Med. ‒ 2000. ‒ № 162. – Р. 1109-1114.Takahashi H., Fujishima T., Koba H., Murakami S., Kurokawa K., Shibuya Y., Shiratori M, Kuroki Y., Abe S. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am. J. Respir. Crit. Care Med., 2000, no. 162, pp. 1109-1114.Tamura M., Saraya T., Fujiwara M., Hiraoka S., Yokoyama T., Yano K., Ishii H., Furuse J., Goya T., Takizawa H., Goto H. High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases // Oncologist. ‒ 2013. ‒ № 18 (4). – Р. 454.Tamura M., Saraya T., Fujiwara M., Hiraoka S., Yokoyama T., Yano K., Ishii H., Furuse J., Goya T., Takizawa H., Goto H. High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases. Oncologist, 2013, no. 18 (4), pp. 454.Torrisi J. M., Schwartz L. H., Gollub M. J., Ginsberg M. S., Bosl G. J., Hricak H. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity // Radiology. ‒ 2011. ‒ № 258(1). – Р. 41-56.Torrisi J.M., Schwartz L.H., Gollub M.J., Ginsberg M.S., Bosl G.J., Hricak H.CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology, 2011, no. 258 (1), pp. 41-56.Vahid B., Marik P. E. Pulmonary complications of novel antineoplastic agents for solid tumors // Chest. ‒ 2008. ‒ № 133. – Р. 528-538.Vahid B., Marik P.E. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest, 2008, no. 133, pp. 528-538.Vander Els. N. J., Stover D. E. Chemotherapy-Induced Lung Disease // Clin. Pulmon. Med. ‒ 2004. – Vol. 11, № 2. – Р. 84-91.Vander Els. N.J., Stover D.E. Chemotherapy-induced lung disease. Clin. Pulmon. Med., 2004, vol. 11, no. 2, pp. 84-91.Zarogoulidis P., Chatzaki E., Porpodis K., Domvri K., Hohenforst-Schmidt W., Goldberg E. P., Karamanos N., Zarogoulidis K. Inhaled chemotherapy in lung cancer: Future concept of nanomedicine // Int. J. Nanomed. ‒ 2012. ‒ № 7. – Р. 1551-1572.Zarogoulidis P., Chatzaki E., Porpodis K., Domvri K., Hohenforst-Schmidt W., Goldberg E.P., Karamanos N., Zarogoulidis K. Inhaled chemotherapy in lung cancer: Future concept of nanomedicine. Int. J. Nanomed, 2012, no. 7, pp. 1551-1572.

The authors declare that there are no conflicts of interest present.